TransPass™ HUVEC Transfection Reagent

  • Catalog # M2558 was discontinued on January 01, 2013
  • Product Information
    This product includes 2 x 0.6 ml TransPass-V (store at -20°C) and 0.6 ml HUVEC Reagent Component (store at 4°C).

    The TransPass™ HUVEC Transfection Reagent is designed specifically for transfecting endothelial cells including HUVEC, HMVEC, human aortic endothelial cells, etc. with optimal transfection efficiency (Figure 1). TransPass HUVEC Transfection Reagent consists of two components: the HUVEC Reagent Component, a non-lipid cationic transfection reagent, and TransPass-V*, an Adenovirus-derived component.

    The addition of TransPass-V significantly enhances lipid-mediated transfection efficiency in many cell lines and primary cells including endothelial or epithelial (1,2).

    The combination with the HUVEC Reagent Component yields optimal plasmid DNA transfection efficiency in HUVEC and many endothelial cell lines (Figure  2).

    * TransPass-V contains a replication-deficient Adenovirus preparation. Because of the nature of this component, it should not be used with cell lines that contain Adenovirus sequences such as HEK-293, to avoid complementation of the virus. Additionally, it is recommended that common laboratory biosafety used in standard Adenovirus work should be practiced. For more information see

    TransPass HUVEC and TransPass V are proprietary formulations manufactured by Targeting Systems. Please direct all inquiries regarding reagent compositions to Targeting Systems.

    Cell Lines Successfully Transfected:
    • HUVEC cells (Human umbilical vein endothelial cells (70-90%)
    • Dermal microvascular endothelial cells (40%)
    • Lung microvascular endothelial cells (70-90%)
    • Human aortic endothelial cells (50%)
    • Bovine aortic endothelial cells (60-70%)
    • Rat endothelial cells (60-70%)
    Guidelines for Endothelial Cell Culture:
    • Use early passages of cells (up to the 6th passage) for transfections.
    • Use non-collagen and non-gelatin coated tissue culture plates only (transfection of cells plated on collagen-coated surfaces may result in lower transfection efficiency).
    • Recommended media: MCDB131 from VEC technologies, Media 199 plus supplements and 20% fetal calf serum or EBM from Cambrex plus supplements and 10% fetal calf serum. Cells grown in these media appear healthier and give higher transfection efficiency.
    • Clonetics HUVEC cells have given very good transfection results.
    Transfection Guidelines:
    • For consistent results, it is important to maintain healthy proliferating cells that are regularly passaged.
    • If cells have been grown in medium containing heparin, they must be washed after trypsinizing and resuspended in growth medium without heparin and antibiotics/antimycotics before plating for transfection.
    • It is important that NO heparin and NO antibiotics/antimycotics are present in the growth medium during transfection.
    • Use sterile plasmid DNA purified by CsCl gradient centrifugation or column chromatography.
    • The amount of plasmid DNA per transfection can be varied, and the ratio of HUVEC Reagent Component to TransPass-V should be kept between (1:1) and (1:2).

    Figure 1:
    Transfection of primary Human Umbilical Vein Endothelial Cells (HUVEC) with a GFP-expressing vector using TransPass HUVEC Transfection Reagent. A transfection complex mixture composed of 6 µg of GFP expressing plasmid, 12 µl of HUVEC Reagent Component and 25 µl TransPass-V in 0.5 ml of high glucose media was added to a 60-mm dish of HUVEC in freshly supplmented EBM containing 10% fetal calf serum, followed by an overnight incubation. Media was replaced with complete growth media on the following day. Data courtesy of Dr. Michael Potente, Department of Cardiology, University of Frankfurt, Germany.
    Figure 2:
    Pooled HUVEC (Cambrex, C2519A)(A) or HUVEC (Cambrex, C2517A) (B) were transfected with pCMV-GLuc Control Plasmid (NEB #N8081), a plasmid expressing secreted Gaussia luciferase, using either HUVEC Reagent Component (HRC) alone or a combination of HRC and TransPass-V. Briefly, cells were transfected in 24-well plate format (approximately 80% cell density) with 0.6 µg pCMV-GLuc in the presence of serum. After 24 hours of transfection, GLuc activity was assayed from the cell supernatant.

    This product is related to the following categories:
    Discontinued Products
    • Properties & Usage
    • Product Notes
    • References
  • Protocols, Manuals & Usage
  • FAQs & Troubleshooting
  • Quality, Safety & Legal
    • Quality Control Assays
    • Safety Data Sheets
    • Legal and Disclaimers
Loading Spinner